A pan-cancer analysis demonstrated the consistent upregulation of NXPH4 across various DSCs, suggesting its diagnostic potential in cholangiocarcinoma, esophageal cancer, liver cancer, and gastric cancer (Fig. S1). This evidence concerns the gene NXPH4 and cholangiocarcinoma.